Skip to content
Poster

Additive hepatoprotective effects of semaglutide and resmetirom combination therapy in the GAN diet-induced obese and biopsy-confirmed mouse model of MASH

Background & Aim: Resmetirom (THR-β receptor agonist) has recently been approved for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and semaglutide (GLP-1R agonist) is in late-stage clinical development for treatment of MASH. The present study aimed to characterize metabolic, biochemical, histological and transcriptomic outcomes of resmetirom and semaglutide combination treatment in the translational GAN diet-induced obese (DIO) and biopsy-confirmed mouse model of MASH with liver fibrosis.

Subjects
GAN DIO-MASH mouseMouseBody weightBlood biochemistryBioinformaticsMetabolic dysfunction-associated steatohepatitisGLP-1 receptorHistopathology scoreImage analysisImmunohistochemistry (IHC)Liver biopsyLiver morphometryNext-generation sequencingRNA sequencingTHR-ß receptorResmetiromSemaglutide

For further information

Contact us

Gubra

Hørsholm Kongevej 11B
2970 Hørsholm
Denmark

+45 3152 ­2650

Back To Top